Cantor Fitzgerald Maintains Neutral Rating on Pfizer (PFE) With Positive EPS Outlook for 2025-2026

Pfizer Inc. (NYSE:PFE) ranks among the best stocks to buy for retirement. Cantor Fitzgerald reiterated its Neutral rating on Pfizer Inc. (NYSE:PFE) on August 13 and set a $24 price target. The firm recognized Pfizer’s potential to beat peers with slower growth and generate earnings per share. In particular, Cantor Fitzgerald highlighted Pfizer’s performance in light of Bristol Myers Squibb’s difficulties with ADEPT-2 and Merck’s unclear fiscal year 2025 guidance.

Pixabay/Public Domain

That said, Cantor Fitzgerald believes that the pharmaceutical company’s long-term growth issues will limit the potential increase in value of Pfizer’s shares, even with its solid execution.

Despite this, the firm estimates that Pfizer’s EPS projections for 2025 and 2026 could go up, exceeding the market’s current forecasts for those years.

Pfizer Inc. (NYSE:PFE) is a leading global pharmaceutical company that develops, produces, and sells biopharmaceutical medicines worldwide.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.